Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 356.5 EUR 0.14%
Market Cap: 3B EUR

Virbac SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Virbac SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Virbac SA
PAR:VIRP
Cash from Operating Activities
€196.2m
CAGR 3-Years
33%
CAGR 5-Years
6%
CAGR 10-Years
10%
Sanofi SA
PAR:SAN
Cash from Operating Activities
€11.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Cash from Operating Activities
€897.2m
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
15%
Vetoquinol SA
PAR:VETO
Cash from Operating Activities
€70.9m
CAGR 3-Years
16%
CAGR 5-Years
-2%
CAGR 10-Years
6%
Boiron SA
PAR:BOI
Cash from Operating Activities
€52.9m
CAGR 3-Years
-8%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Medincell SA
PAR:MEDCL
Cash from Operating Activities
€19.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Virbac SA
Glance View

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

VIRP Intrinsic Value
HIDDEN
Show

See Also

What is Virbac SA's Cash from Operating Activities?
Cash from Operating Activities
196.2m EUR

Based on the financial report for Jun 30, 2025, Virbac SA's Cash from Operating Activities amounts to 196.2m EUR.

What is Virbac SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for Virbac SA have been 33% over the past three years , 6% over the past five years , and 10% over the past ten years .

Back to Top